A 26-Week, Open-Label, Randomized, Active Comparator Study of Generex Oral-Lyn [insulin; Generex Biotechnology Corporation] Spray and Injected Human Insulin In Subjects With Type-1 Diabetes Mellitus

Trial Profile

A 26-Week, Open-Label, Randomized, Active Comparator Study of Generex Oral-Lyn [insulin; Generex Biotechnology Corporation] Spray and Injected Human Insulin In Subjects With Type-1 Diabetes Mellitus

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Oct 2013

At a glance

  • Drugs Insulin; Insulin
  • Indications Type 1 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Jul 2011 Preliminary results published in a Generex Media Release.
    • 16 Jun 2011 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top